Source:

Press Release

February 07, 2021
1 min read
Save

Durect receives FDA approval for local analgesic following subacromial decompression

Source:

Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Durect Corporation has announced the FDA approval of Posimir, a post-surgical, non-opioid local analgesic for patients who undergo arthroscopic subacromial decompression surgery, according to a press release.

Posimir’s solution includes a 660-mg bupivacaine base and is designed for administration into the subacromial space under direct arthroscopic visualization. The solution provides post-surgical analgesia for up to 72 hours, according to the release.

“We are excited to announce the approval of Posimir, a novel, non-opioid, sustained-release local analgesic for the treatment of post-surgical pain following arthroscopic subacromial decompression surgery,” James E. Brown, president and CEO of Durect, said in the release. “This FDA approval provides an important new option to help orthopedic surgeons in their efforts to minimize opioid use while managing acute pain for up to 72 hours after this painful surgery,” he added.